Crinetics Pharmaceuticals, Inc.

Equities

CRNX

US22663K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
43.32 ^USD	-2.04%		-1.57%	+21.75%

Apr. 17	Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing	MT
Mar. 26	Crinetics Pharmaceuticals Insider Sold Shares Worth $1,433,675, According to a Recent SEC Filing	MT

Crinetics Pharmaceuticals : ENDO 2021

February 28, 2021 at 02:52 am EST

[Link]

Attachments

Original document
Permalink

Disclaimer

Crinetics Pharmaceuticals Inc. published this content on 27 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 February 2021 07:51:03 UTC.

Latest news about Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing	Apr. 17	MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $1,433,675, According to a Recent SEC Filing	Mar. 26	MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $664,763, According to a Recent SEC Filing	Mar. 22	MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $2,648,150, According to a Recent SEC Filing	Mar. 22	MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $449,793, According to a Recent SEC Filing	Mar. 21	MT
JMP Securities Adjusts Price Target on Crinetics Pharmaceuticals to $80 From $60, Maintains Market Outperform Rating	Mar. 20	MT
Oppenheimer Raises Crinetics Pharmaceuticals Price Target to $55 From $54, Maintains Outperform Rating	Mar. 20	MT
JonesTrading Raises Crinetics Pharmaceuticals' Price Target to $56 From $52, Maintains Buy Rating	Mar. 20	MT
HC Wainwright Raises Crinetics Pharmaceuticals Price Target to $60 From $50, Maintains Buy Rating	Mar. 20	MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	Mar. 19	MT
Correction: Crinetics Pharmaceuticals Says Phase 3 Trial for Acromegaly Treatment Meets Endpoints; Shares Rise Pre-Bell	Mar. 19	MT
Crinetics Pharmaceuticals Says Phase 3 Trial for Acromegaly Treatment Meets Endpoints; Shares Rise Pre-Bell	Mar. 19	MT
Transcript : Crinetics Pharmaceuticals, Inc. - Special Call	Mar. 19
Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study	Mar. 19	RE
Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly	Mar. 19	CI
Oppenheimer Adjusts Crinetics Pharmaceuticals Price Target to $54 From $48, Maintains Outperform Rating	Mar. 13	MT
Crinetics Pharmaceuticals Up in Extended Hours After Positive Top-Line Results for Drug Candidate	Mar. 12	MT
Transcript : Crinetics Pharmaceuticals, Inc. - Special Call	Mar. 12
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome	Mar. 12	CI
HC Wainwright Adjusts Crinetics Pharmaceuticals Price Target to $50 From $42, Maintains Buy Rating	Mar. 08	MT
Citigroup Initiates Crinetics Pharmaceuticals With Buy Rating, $68 Price Target	Mar. 06	MT
Cantor Fitzgerald Adjusts Price Target on Crinetics Pharmaceuticals to $65 From $50, Maintains Overweight Rating	Mar. 04	MT
Crinetics Pharmaceuticals, Inc. announced that it has received $350.000028 million in funding from a group of investors	Feb. 29	CI
Oppenheimer Raises Crinetics Pharmaceuticals Price Target to $48 From $46, Maintains Outperform Rating	Feb. 29	MT
Baird Adjusts Crinetics Pharmaceuticals Price Target to $52 From $45, Maintains Outperform Rating	Feb. 29	MT

Chart Crinetics Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Crinetics Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

43.32 USD

Average target price

57.23 USD

Spread / Average Target

+32.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CRINETICS PHARMACEUTICALS, INC.	+21.75%	3.38B
IQVIA HOLDINGS INC.	+4.09%	43.84B
MODERNA, INC.	+9.45%	41.68B
LONZA GROUP AG	+46.00%	41.25B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research